NutraLife BioSciences, Inc. Logo

NutraLife BioSciences, Inc.

NLBS

(2.2)
Stock Price

0,00 USD

0% ROA

0% ROE

0x PER

Market Cap.

17.662,00 USD

0% DER

0% Yield

0% NPM

NutraLife BioSciences, Inc. Stock Analysis

NutraLife BioSciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

NutraLife BioSciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (3734.99%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

With a remarkably low PBV ratio (-0.02x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-441%), which means it has a small amount of debt compared to the ownership it holds

4 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

6 ROA

The stock's ROA (-177.61%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

NutraLife BioSciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

NutraLife BioSciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

NutraLife BioSciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

NutraLife BioSciences, Inc. Revenue
Year Revenue Growth
2012 126.576
2013 597.777 78.83%
2014 62.274 -859.91%
2015 193.998 67.9%
2016 391.855 50.49%
2017 1.790.168 78.11%
2018 3.711.327 51.76%
2019 2.133.624 -73.94%
2020 1.255.784 -69.9%
2021 626.619 -100.41%
2022 460.596 -36.05%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

NutraLife BioSciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 20.826
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

NutraLife BioSciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 405.554
2013 1.947.366 79.17%
2014 1.005.765 -93.62%
2015 1.488.830 32.45%
2016 1.323.358 -12.5%
2017 20.865.095 93.66%
2018 3.140.764 -564.33%
2019 3.720.874 15.59%
2020 2.306.472 -61.32%
2021 4.418.885 47.8%
2022 1.893.060 -133.43%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

NutraLife BioSciences, Inc. EBITDA
Year EBITDA Growth
2012 -386.980
2013 -1.971.078 80.37%
2014 -1.577.986 -24.91%
2015 -1.614.157 2.24%
2016 -1.002.944 -60.94%
2017 -20.209.198 95.04%
2018 -1.874.754 -977.97%
2019 -3.769.019 50.26%
2020 -2.482.437 -51.83%
2021 -4.139.777 40.03%
2022 -1.116.672 -270.72%
2022 0 0%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

NutraLife BioSciences, Inc. Gross Profit
Year Gross Profit Growth
2012 51.749
2013 250.816 79.37%
2014 -290.048 186.47%
2015 73.097 496.8%
2016 359.033 79.64%
2017 735.126 51.16%
2018 1.500.288 51%
2019 598.134 -150.83%
2020 509.850 -17.32%
2021 83.588 -509.96%
2022 378.248 77.9%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

NutraLife BioSciences, Inc. Net Profit
Year Net Profit Growth
2012 -387.748
2013 -2.083.359 81.39%
2014 -2.075.720 -0.37%
2015 -2.101.061 1.21%
2016 -1.528.589 -37.45%
2017 -23.629.117 93.53%
2018 -2.074.537 -1039.01%
2019 -4.073.348 49.07%
2020 -2.902.682 -40.33%
2021 -7.683.241 62.22%
2022 -7.642.808 -0.53%
2022 0 0%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

NutraLife BioSciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

NutraLife BioSciences, Inc. Free Cashflow
Year Free Cashflow Growth
2012 -372.348
2013 -1.141.495 67.38%
2014 -1.258.202 9.28%
2015 -895.608 -40.49%
2016 -687.458 -30.28%
2017 -1.189.185 42.19%
2018 -816.305 -45.68%
2019 -4.528.935 81.98%
2020 -1.284.240 -252.65%
2021 -487.386 -163.5%
2022 0 0%
2022 -943.160 100%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

NutraLife BioSciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 -290.983
2013 -902.486 67.76%
2014 -1.231.077 26.69%
2015 -850.679 -44.72%
2016 -671.152 -26.75%
2017 -1.018.070 34.08%
2018 -234.673 -333.82%
2019 -2.934.441 92%
2020 -1.284.240 -128.5%
2021 -487.386 -163.5%
2022 0 0%
2022 -439.960 100%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

NutraLife BioSciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 81.365
2013 239.009 65.96%
2014 27.125 -781.14%
2015 44.929 39.63%
2016 16.306 -175.54%
2017 171.115 90.47%
2018 581.632 70.58%
2019 1.594.494 63.52%
2020 0 0%
2021 0 0%
2022 0 0%
2022 503.200 100%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

NutraLife BioSciences, Inc. Equity
Year Equity Growth
2012 -167.104
2013 -71.100 -135.03%
2014 -949.329 92.51%
2015 -180.679 -425.42%
2016 -260.789 30.72%
2017 660.523 139.48%
2018 815.254 18.98%
2019 1.589.117 48.7%
2020 301.110 -427.75%
2021 -712.530 142.26%
2022 0 0%
2022 -2.315.288 100%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

NutraLife BioSciences, Inc. Assets
Year Assets Growth
2012 248.889
2013 647.529 61.56%
2014 345.695 -87.31%
2015 2.210.703 84.36%
2016 2.395.499 7.71%
2017 954.132 -151.07%
2018 1.830.329 47.87%
2019 4.465.691 59.01%
2020 4.706.708 5.12%
2021 4.851.125 2.98%
2022 0 0%
2022 6.032.757 100%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

NutraLife BioSciences, Inc. Liabilities
Year Liabilities Growth
2012 415.993
2013 718.629 42.11%
2014 1.295.024 44.51%
2015 2.391.382 45.85%
2016 2.656.288 9.97%
2017 293.609 -804.7%
2018 1.015.075 71.08%
2019 2.876.574 64.71%
2020 4.405.598 34.71%
2021 5.563.655 20.81%
2022 0 0%
2022 8.348.045 100%
2023 0 0%

NutraLife BioSciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

NutraLife BioSciences, Inc. Dividends
Year Dividends Growth

NutraLife BioSciences, Inc. Profile

About NutraLife BioSciences, Inc.

NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil derived from industrial hemp; tinctures; topical lotions and oils applied directly to the skin to treat pain or inflammation; face creams; massage oils; nutraceutical sprays with CBD as an added ingredient; and pet products. The company also offers other products, such as skincare and sanitizer products. NutraLife BioSciences, Inc. sells its products through nutralifebiosciences.com, as well as through private label distributors, online retailers, and retail outlets. The company was formerly known as NutraFuels, Inc. and changed its name to NutraLife BioSciences, Inc. in March 2019. NutraLife BioSciences, Inc. was incorporated in 2010 and is based in Coconut Creek, Florida.

CEO
Mr. Edgar Ward
Employee
12
Address
6601 Lyons Road
Coconut Creek, 33073

NutraLife BioSciences, Inc. Executives & BODs

NutraLife BioSciences, Inc. Executives & BODs
# Name Age
1 Mr. Nicholas E Ward
Project & Operations Manager
70
2 Dr. Kenneth L Duchin Ph.D.
Chief Clinical Developer
70
3 Mr. Edgar Ward
Founder, President, Chief Executive Officer & Director
70
4 Dr. Hongxiang Hui M.D., Ph.D.
Chief Medical Advisor & Member of Advisory Board
70

NutraLife BioSciences, Inc. Competitors